… therapies available in Israel are anti–tumor necrosis factor-α (TNF-α), the interleukin (IL)
12/23 p40 monoclonal antibody ustekinumab, … the safety of using biologics in this setting. The …

… Concomitant hepatitis B virus and hepatitis C virus infections … new HIV-infected cases in
our setting in the last decade, as … and ustekinumab, seem to have an acceptable safety profile …

… The study outcomes indicate that ustekinumab could be safe … of biologic agents including
anti-tumor necrosis factor (TNF)-… of retrospective studies involving psoriasis patients using …

… option for individuals with psoriasis and chronic viral hepatitis. … Safety and efficacy of
anti‐tumor necrosis factors alpha in … viral hepatitis B or C: a retrospective, multicentre study in a …

… on the safety of biological therapies in psoriasis patients with … positive patients treated with
anti-tumor necrosis factor (TNF) … with HBV using ustekinumab and secukinumab for psoriasis …

… Nevertheless, safety data are scarce for the use of biologics … with psoriasis treated with
biologics in a real-world setting are … /23 inhibitor (IL-12/23i; ustekinumab), and IL-17 inhibitor (IL-…

… in psoriasis, CD, and ulcerative colitis by ustekinumab[17-19], … A retrospective study on 44
patients with resolved HBV who … A prospective multicenter study on 22 patients with CHB with …

… -hepatitis B core antigen-positive patients treated with tumor necrosis factor-α inhibitors,
ustekinumab, … recent reports of the safe use of anti-tumor necrosis factor agents in these patients. …

… A recent multicenter, retrospective study evaluated the safety of adalimumab in … of TNF-α
inhibitors in treating psoriasis and IBD may be a safe and effective option after receiving organ …

… a multicentre study to assess the risk of virus reactivation in … HCV reactivation during
ustekinumab therapy (6). In this … Safety of anti-tumour necrosis factor agents in patients with …